HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MRPL33
mitochondrial ribosomal protein L33
Chromosome 2 · 2p23.2
NCBI Gene: 9553Ensembl: ENSG00000243147.9HGNC: HGNC:14487UniProt: O75394
40PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
mitochondrionmitochondrial large ribosomal subunitmitochondrial translationmitochondrial inner membraneneurodegenerative diseaselymphoid leukemiagoutlysosomal storage disease
✦AI Summary

MRPL33 encodes a large subunit protein of the mitochondrial ribosome involved in mitochondrial translation 1. The gene produces two isoforms through alternative splicing: the long form (MRPL33-L) containing exon 3 and the short form (MRPL33-S) lacking exon 3, with distinct functional roles 2. MRPL33-L depletion impairs mitochondrial function, increasing reactive oxygen species accumulation and decreasing ATP production and 16S rRNA levels 1. In cancer biology, MRPL33-L promotes tumor cell proliferation and survival. Its splicing is regulated by hnRNPK and RBM39 in different cancer types; elevated MRPL33-L inclusion correlates with enhanced tumorigenicity in colorectal and gastric cancers 1 3. Conversely, MRPL33-S promotes chemosensitivity to epirubicin in gastric cancer by deactivating PI3K/AKT signaling 2. Beyond cancer, MRPL33 shows dysregulated expression in diverse conditions: reduced expression in congenital hypothyroidism associates with impaired thyroid function via IL-2/STAT5 pathways 4, elevated levels protect against primary biliary cholangitis 5, and altered expression correlates with tuberculosis progression 6. These findings establish MRPL33 as a multi-functional biomarker whose isoform composition and expression levels influence mitochondrial function, immune regulation, and disease progression across multiple pathologies.

Sources cited
1
MRPL33-L is a mitoribosomal large subunit protein required for mitochondrial translation; its depletion causes mitochondrial dysfunction with increased ROS, decreased ATP, and impaired 16S rRNA levels; splicing regulated by hnRNPK
PMID: 28869607
2
RBM39 regulates MRPL33 alternative splicing; MRPL33-L (exon 3-containing form) promotes gastric cancer cell proliferation; MRPL33-S (exon 3-skipping form) does not promote proliferation
PMID: 39753980
3
MRPL33-L and MRPL33-S have opposing roles in epirubicin chemosensitivity; MRPL33-S enhances chemosensitivity by deactivating PI3K/AKT/CREB signaling, while MRPL33-L suppresses chemosensitivity
PMID: 30816492
4
MRPL33 is a hub gene with low expression in congenital hypothyroidism; negatively regulates IL-2 and acts through STAT5/MTORC1 pathways to regulate thyroid cell function and FT4 synthesis
PMID: 41169358
5
Elevated MRPL33 levels associate with decreased risk of primary biliary cholangitis in Mendelian randomization analysis
PMID: 38857754
6
MRPL33 identified as a core biomarker for tuberculosis progression; Mtb infection alters MRPL33 expression patterns in THP-1 cells
PMID: 39856190
7
MRPL33 identified as a circulating biomarker for prostate cancer through proteome-wide Mendelian randomization analysis
PMID: 39933395
8
MRPL33 identified as a potential diagnostic and therapeutic biomarker for pituitary neuroendocrine tumors through enhancer RNA analysis
PMID: 37534217
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.50Moderate
lymphoid leukemiaOpen Targets
0.39Weak
goutOpen Targets
0.35Weak
Alzheimer diseaseOpen Targets
0.33Weak
lysosomal storage diseaseOpen Targets
0.33Weak
multiple sclerosisOpen Targets
0.33Weak
Parkinson diseaseOpen Targets
0.33Weak
major depressive disorderOpen Targets
0.28Weak
infectious diseaseOpen Targets
0.28Weak
schizophreniaOpen Targets
0.28Weak
metabolic syndromeOpen Targets
0.26Weak
bipolar disorderOpen Targets
0.23Weak
attention deficit hyperactivity disorderOpen Targets
0.17Weak
nephrolithiasisOpen Targets
0.16Weak
Abnormality of the skeletal systemOpen Targets
0.15Weak
autism spectrum disorderOpen Targets
0.15Weak
anorexia nervosaOpen Targets
0.15Weak
obsessive-compulsive disorderOpen Targets
0.15Weak
Tourette syndromeOpen Targets
0.15Weak
risk-taking behaviourOpen Targets
0.14Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
MRPL55Shared pathway100%MRPL52Protein interaction100%ABCF1Protein interaction100%HMGN2Protein interaction100%OXA1LProtein interaction100%RPL23AProtein interaction100%
Tissue Expression6 tissues
Heart
100%
Lung
54%
Brain
50%
Liver
41%
Ovary
40%
Bone Marrow
27%
Gene Interaction Network
Click a node to explore
MRPL33MRPL55MRPL52ABCF1HMGN2OXA1LRPL23A
PROTEIN STRUCTURE
Preparing viewer…
PDB7OF0 · 2.20 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.14LoF Tolerant
pLIⓘ
0.16Tolerant
Observed/Expected LoF0.50 [0.24–1.14]
RankingsWhere MRPL33 stands among ~20K protein-coding genes
  • #10,207of 20,598
    Most Researched40
  • #11,751of 17,882
    Most Constrained (LOEUF)1.14
Genes detectedMRPL33
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.
PMID: 28869607
Oncogene · 2018
1.00
2
RNA-binding motif protein RBM39 enhances the proliferation of gastric cancer cells by facilitating an oncogenic splicing switch in MRPL33.
PMID: 39753980
Acta Pharmacol Sin · 2025
0.90
3
Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
PMID: 37534217
Front Endocrinol (Lausanne) · 2023
0.80
4
Identification of hub genes in congenital hypothyroidism and construction of the associated immune regulatory network.
PMID: 41169358
Front Immunol · 2025
0.70
5
Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome.
PMID: 39933395
J Pharm Biomed Anal · 2025
0.60